The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
The conversation is about finding a trustworthy supplier for Pyrilutamide, a hair loss treatment. The user previously purchased RU58841 from Anagenic and is considering them for Pyrilutamide.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
The conversation discusses hair loss treatments, specifically RU58841, and inquiries about its availability and cost in India. Minoxidil and finasteride are also mentioned as treatments.
Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
41-year-old female experienced slow hair thinning, took finasteride for a year, then switched to spironolactone. Irregular periods occurred, seeking advice on long-term side effects and considering a third medication.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A 26-year-old male has been using finasteride for 4.5 years to maintain hair and recently started taking dutasteride weekly due to increased hair shedding. He plans to gradually switch to dutasteride while monitoring side effects and hair changes.
RU58841 is discussed for hair loss treatment, with mixed reviews on its effectiveness and side effects. Users mention using it in an ethanol/PG solution and combining it with other treatments like dutasteride.
A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.
The conversation is about finding genuine sources to buy Pyrilutamide in India and possibly importing it as a group to reduce costs. The user seeks advice on shipping without prescription issues.
The conversation is about a 37-year-old's three-year hair loss treatment with Minoxidil and Finasteride, and one week on RU58841. The user is seeking further improvement, which they describe as "greed."
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
RU58841 is being discussed for its effects on hair loss. The user has started using RU58841 with finasteride and is curious about its potential for hair maintenance or regrowth.
The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.
People are not using RU58841 for hair loss because it's not FDA approved, lacks long-term safety data, and is difficult to obtain and verify. They prefer FDA-approved treatments like minoxidil, finasteride, ketoconazole shampoo, and microneedling.
A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.
The conversation is about a group of people trying KX-826 for hair loss, with no serious side effects reported after 25 days of use. Some participants are experiencing less scalp itch and shedding, but it's too early for definitive results.
OP bought Koshine x826 and plans to update on its effectiveness, currently using fluridil. OP couldn't tolerate RU or DUT, while another user mixes Dutasteride with Koshine x826 weekly without side effects.
Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.